MGF (Mechano Growth Factor): The IGF-1 Splice Variant Behind Muscle Repair

MGF, short for Mechano Growth Factor, is not a separate hormone at all but a special version of IGF-1 that your muscles make for themselves when they are mechanically loaded or damaged. Technically it is a splice variant of the IGF-1 gene, called IGF-1Ec in humans, and its job is to wake up the muscle stem cells that rebuild a fiber after a hard workout or an injury. That local, repair-triggering role is why it became one of the most discussed muscle peptides in the biohacking world.

The catch sits in two facts. First, almost everything we know about MGF as a muscle-builder comes from cell-culture and animal work, not human trials of an injected peptide. Second, your body's own MGF lasts only minutes before it is broken down, which is exactly why a longer-lasting, pegylated version called PEG-MGF was created for research use. This guide is the high-level map of the whole compound: what MGF actually is, how its unique E-domain activates satellite cells, how it differs from a full-length analog like IGF-1 LR3, what the evidence does and does not show, the doses people report, and its research-only legal status. The deep-dive spokes (full PEG-MGF dosing, side-effect management) link out so this page stays a clean hub, and for the wider field see our roundup of the best peptides for muscle growth.

Key Takeaways

• MGF (Mechano Growth Factor) is a splice variant of IGF-1, named IGF-1Ec in humans, produced locally by muscle that has been mechanically loaded or damaged; it is the same IGF-1 gene read in a different way, not a different gene (Schlegel et al., PLoS ONE, 2013, retrieved 2026-06-16).
• Its defining feature is a unique C-terminal "E-domain" peptide (the 24-amino-acid MGF E-peptide, sequence YQPPSTNKNTKSQRRKGSTFEERK) that activates muscle satellite cells, and it appears to do so independently of the IGF-1 receptor (Kandalla et al., Mechanisms of Ageing and Development, 2011, retrieved 2026-06-16).
• Native MGF has a very short half-life and is rapidly metabolized in vivo, which is the whole reason a pegylated research version, PEG-MGF, was created to make it last longer (Zabłocka et al., Frontiers in Endocrinology, 2012, retrieved 2026-06-16).
• The muscle-growth case is mechanistic, not proven in people. Evidence comes from in-vitro human muscle-cell and animal studies; there is no completed human clinical trial showing the injected MGF/PEG-MGF peptide builds muscle, and its "efficacy in man is not proven" (Zabłocka et al., 2012, retrieved 2026-06-16).
• It is not FDA-approved and is sold research-use-only. Reported PEG-MGF doses (often described around 200-400 mcg post-workout) are a community/research convention, not a validated or recommended dose, because no human dose-finding study exists.
• It is banned in sport. MGF appears by name on the World Anti-Doping Agency Prohibited List among growth factors (class S2), prohibited at all times (WADA Prohibited List, S2, retrieved 2026-06-16).

What is MGF (Mechano Growth Factor)?

MGF is a locally produced splice variant of IGF-1, called IGF-1Ec in humans, that muscle releases when it is mechanically stressed or injured, to kick-start its own repair. The name captures the idea exactly: a growth factor switched on by mechanical load. It is studied mainly for muscle regeneration, and as an injected research peptide it is not an approved medicine.

To understand MGF, start with the IGF-1 gene. The IGF-1 gene has six exons, and the body can splice them together in different ways to produce different "E-domain" tails on the same core IGF-1 protein. The dominant liver-made version is IGF-1Ea. When muscle is loaded or damaged, it instead produces IGF-1Ec, the variant nicknamed MGF, in which part of exon 5 is spliced to exon 6, shifting the reading frame and creating a distinct C-terminal peptide (Schlegel et al., "Insulin-Like Growth Factor I (IGF-1) Ec/Mechano Growth Factor", PLoS ONE, 2013, retrieved 2026-06-16). So MGF is not a foreign molecule; it is your own IGF-1 gene read in a "repair" dialect. In rodent studies the equivalent variant is usually labeled IGF-1Eb, which is why the naming can look inconsistent across papers.

The single most important framing for the injected product: the synthetic "MGF" sold to researchers is usually just the unique 24-amino-acid E-domain peptide (the "MGF E-peptide"), not the full protein, and it is not approved by any regulator for human use. If injectable peptides are new to you, start with our what are peptides and how peptides work guides.

Citation capsule. MGF (Mechano Growth Factor) is the IGF-1Ec splice variant of human IGF-1 (gene IGF1; protein UniProt P05019), produced by mechanically loaded or damaged muscle, in which part of exon 5 splices to exon 6 to create a distinct C-terminal E-domain. The synthetic research peptide is typically the 24-amino-acid MGF E-peptide (sequence Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys / YQPPSTNKNTKSQRRKGSTFEERK). It is rapidly metabolized in vivo and is not approved by any regulator. Source: Schlegel et al., PLoS ONE, 2013; Zabłocka et al., Frontiers in Endocrinology, 2012; Wikipedia, "Mechano growth factor," 2026; UniProt P05019.

How does MGF work?

MGF is thought to work by activating satellite cells, the dormant stem cells that sit alongside muscle fibers, telling them to wake up, multiply, and fuse in to rebuild damaged muscle. Its unique E-domain peptide appears to drive this satellite-cell step, and, unusually, it seems to act independently of the IGF-1 receptor. As with most of MGF's story, this picture comes from cell and animal studies, not human trials.

In plain terms, a heavy or damaging bout of exercise is the trigger. The muscle splices out MGF (IGF-1Ec) as an early, local "pulse," and that pulse recruits satellite cells to start the repair before the slower, more systemic IGF-1Ea response takes over for the building phase. The key research finding is that the E-domain on its own is active: "MGF-24aa-E peptide alone has a marked ability to enhance satellite cell activation, proliferation and fusion for muscle repair," and it did so in human muscle progenitor cells across different ages (Kandalla et al., "Mechano Growth Factor E peptide (MGF-E)... activates human muscle progenitor cells", Mechanisms of Ageing and Development, 2011, retrieved 2026-06-16).

Here is what each proposed piece contributes, in simple terms:

• Satellite-cell activation (the headline action): the E-peptide wakes dormant muscle stem cells and pushes them to proliferate, the first step of repair.
• Receptor independence: because the E-domain lacks the IGF-1-receptor binding site, neutralizing the IGF-1 receptor blocks IGF-1 but not MGF, so MGF's effect "can be separated from receptor activation" (Schlegel et al., 2013, retrieved 2026-06-16).
• An early pulse, then handoff: MGF is framed as the fast, local repair signal; the more familiar IGF-1Ea handles the later anabolic, fiber-building phase.
• Low oncogenic signal in vitro: the E-peptide increased the cells' proliferative lifespan "without the oncogenic side effects observed for IGF1" in that culture work (Kandalla et al., 2011, retrieved 2026-06-16).

The receptor-and-signaling deep dive (how the splice is regulated, why receptor independence matters) is its own topic. We keep it at overview level here and link to how peptides work for the foundations.

How is MGF different from IGF-1 LR3 and full IGF-1?

MGF and IGF-1 LR3 are easy to confuse but are opposites in design: MGF is a short-lived, local repair signal (the E-domain that wakes satellite cells), while IGF-1 LR3 is a long-acting, full-length IGF-1 analog built to flood the IGF-1 receptor for hours. They come from the same parent molecule, IGF-1, but do almost opposite jobs.

The cleanest way to hold them apart is duration and target. Native IGF-1 lasts only minutes; MGF, the E-peptide, is also rapidly metabolized and acts as a brief, local pulse that recruits muscle stem cells largely without the IGF-1 receptor. IGF-1 LR3 is engineered for the reverse: a modified full IGF-1 that dodges its clearance proteins to stay active for roughly a day and keeps signaling through the IGF-1 receptor systemically. So MGF is the "start the repair crew" signal, and IGF-1 LR3 is the "keep the growth signal on" analog. This is a hub-level contrast on purpose; the full IGF-1 LR3 story is its own article: see the complete IGF-1 LR3 guide.

A quick orientation table (reported / mechanistic framing, not a recommendation):

The growth-hormone axis connection (because MGF sits downstream of the GH and IGF-1 system) is also a light touch here; for the GH-axis releasers, see CJC-1295 and the broader how peptides work primer.

Why does MGF have such a short half-life (and why does PEG-MGF exist)?

MGF's natural half-life is very short, on the order of minutes, because the small E-peptide is rapidly broken down and cleared in the body, so a pegylated version called PEG-MGF was created to make it survive long enough to study and use. The short life is a feature of the biology, not a flaw, but it is a problem for anyone trying to inject it.

The E-domain is a tiny peptide. Endogenous E-domains are "predicted to have a very short half-life," and MGF as a whole is described as being "rapidly metabolised in vivo," so an injected pulse of native MGF would be gone almost as fast as the body's own (Zabłocka et al., "Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?", Frontiers in Endocrinology, 2012, retrieved 2026-06-16). PEG-MGF is the engineering answer: attaching a polyethylene-glycol (PEG) chain shields the peptide from rapid breakdown and slows its clearance, stretching its working life from minutes toward hours, which is why PEG-MGF, not plain MGF, is what most research-peptide vendors actually sell.

The specific numbers you will see on supplement sites, such as a "5-7 minute" MGF half-life or a multi-day PEG-MGF half-life, come from vendor and community write-ups, not peer-reviewed pharmacokinetics, so we treat them as community-reported rather than established. The peer-reviewed sources support only the qualitative point: native MGF is very short-lived, and PEGylation meaningfully extends it.

Our take: The existence of PEG-MGF is the most honest clue about plain MGF. If injected native MGF lasted a useful amount of time, no one would have needed to PEGylate it. The half-life problem is real; the precise minute-by-minute figures floating around online are not well sourced.

How strong is the evidence that MGF builds muscle?

The evidence that MGF builds muscle is mechanistic and preclinical: convincing in cell culture and animal models, but with no completed human trial of the injected peptide showing it actually grows muscle in people. That gap between a strong mechanism and a near-empty human file is the single most important thing to understand before considering it.

The strongest support is the in-vitro work on human muscle progenitor cells, where the MGF E-peptide activated and expanded those cells, suggesting a real repair-relevant mechanism (Kandalla et al., 2011, retrieved 2026-06-16). But a leading review is candid about the ceiling on that evidence: MGF's "function is not fully understood and its efficacy in man is not proven," even as it calls the molecule a powerful potential tool (Zabłocka et al., 2012, retrieved 2026-06-16). In other words, the mechanism is interesting and partly demonstrated in human cells in a dish, but that is a long way from a controlled trial showing that injecting MGF or PEG-MGF makes a living person stronger or larger.

Two honest limits sit on top of this. First, "active in human muscle cells in culture" does not establish a dose, a delivery method, or a real-world effect, especially for a peptide that the body clears in minutes. Second, much of the muscle-peptide enthusiasm extrapolates from the natural, locally produced MGF pulse during exercise to an injected synthetic peptide, which is not the same thing. The responsible label for injected MGF as a muscle-builder in humans is investigational, leaning toward unproven.

Our take: MGF has a better-defined mechanism than many hyped peptides, the satellite-cell story is real science. But mechanism is not proof of benefit. We have not found a single completed human trial showing injected MGF or PEG-MGF builds muscle, and "it works in a dish" is exactly the kind of claim that often fails to translate to people.

What doses of MGF (PEG-MGF) do people report using?

There is no validated dose for MGF or PEG-MGF, but reported research and community protocols for PEG-MGF commonly cluster around 200 to 400 mcg, often taken post-workout and sometimes near a worked muscle. These are figures people report, not an established or recommended dose, and there is no approved label or human dose-finding study to anchor them.

Because native MGF is cleared so fast, almost all practical dosing talk is really about PEG-MGF, the longer-lasting version. The most commonly cited community pattern is a single post-workout injection in the low-hundreds-of-micrograms range, a few times per week, with the rationale that the post-exercise window is when satellite-cell recruitment matters most. We label all of this as a community/research convention because no regulator has reviewed a dose, no human pharmacokinetic study defines one, and the figures trace back to vendor and forum write-ups rather than trials. The full PEG-MGF titration ladder, timing logic, and reconstitution math are a dedicated spoke; we keep only the high-level framing here and link to GH-axis peptide context for the adjacent growth-hormone releasers and to how peptides work for the basics.

For orientation only, here is how people commonly describe the reported approach (not a recommendation):

Our take: Numbers like "200 mcg post-workout" get repeated until they sound official. They are not. They are community conventions for the PEGylated version, built on mechanism and habit, not on human dose-finding trials, which is exactly why we never present them as a validated dose.

What are the side effects and risks of MGF?

Because MGF and PEG-MGF have barely been tested in humans, their true side-effect profile is unknown; reported issues are mostly mild, such as injection-site reactions, while the bigger risks are theoretical and tied to growth-factor and product-quality concerns. "Unknown" is the honest headline here, not "safe."

In community use, the commonly described issues are the same low-grade ones reported for most injected peptides, and the laboratory work on the E-peptide was notable for not showing the oncogenic signal seen with full IGF-1 in that culture model (Kandalla et al., 2011, retrieved 2026-06-16). But reassuring cell data are not the same as established human safety. The theoretical concerns that researchers and clinicians flag for any growth-factor peptide still apply, and long-term human data simply do not exist.

A hub-level overview of what is reported and what is theorized:

• Commonly reported (mild, anecdotal): injection-site redness, swelling, or irritation; occasional headache or fatigue.
• Quality-related risks: because the market is unregulated, contamination, mislabeled potency, endotoxin, or impurities are real concerns independent of the peptide itself, and matter a lot for an injected product.
• Theoretical, growth-factor-related: any factor that drives cell proliferation invites caution about unwanted growth; while the E-peptide looked cleaner than IGF-1 in vitro, this has not been established as safe in humans.
• Unknown: true long-term safety in people, because the long-horizon data do not exist.

This is the hub-level summary; a full side-effect deep-dive is a dedicated future spoke. For how to reduce the avoidable, product-side risks, see how to vet peptide quality.

Is MGF safe and legal?

MGF is not approved by any regulator, so there is no official safety determination, and it is not legal to sell or prescribe as an approved medicine or to include in supplements; the products sold online are unapproved "research chemicals," and MGF is banned in sport. That status matters more than any single study.

On legality, MGF (and PEG-MGF) is an unapproved drug: it is sold "for research use only, not for human consumption," it is not a dietary ingredient, and there is no legitimate prescription route for it outside a clinical trial. On sport, it is explicit: MGF is named on the World Anti-Doping Agency Prohibited List among growth factors in class S2, which is prohibited at all times, both in and out of competition (WADA, "The Prohibited List," Section S2, retrieved 2026-06-16; "List of drugs banned by the World Anti-Doping Agency," Wikipedia, retrieved 2026-06-16). For athletes and anyone subject to drug testing, that alone is decisive.

Our take: The most common misunderstanding is assuming that because MGF is sold openly online, it must be legal and vetted to use. It is sold "for research use only," it is an unapproved drug, and it is explicitly banned in sport. Easy to buy is not the same as legal or safe. For the full legal picture, see are peptides legal.

A realistic look at expectations

The "explosive new muscle" stories around MGF come mostly from its mechanism and from anecdotes, not from controlled human results, so realistic expectations should be modest and skeptical. Going in calibrated is part of using any of this information responsibly.

Two honest caveats sit on top of the hype. First, MGF's satellite-cell mechanism, while genuinely demonstrated in cells, has not been shown to translate into measurable muscle gains from an injected peptide in people, and the molecule's very short natural half-life makes that translation harder, not easier. Second, much of what people credit to PEG-MGF, recovery from a hard training block over several weeks, overlaps with what the body would do on its own with progressive training, sleep, and protein. Without controlled trials it is hard to separate signal from normal adaptation. For grounded context on reading transformation claims, see the legal and quality groundwork.

Frequently Asked Questions

The bottom line

MGF is one of the more scientifically grounded names in the muscle-peptide world, and that is exactly why it deserves careful framing. It is not a mystery compound: it is your own IGF-1 gene, spliced into the IGF-1Ec variant when muscle is loaded or damaged, producing an E-domain peptide that wakes satellite cells to start repair, apparently without even needing the IGF-1 receptor. That mechanism is real and partly demonstrated in human cells.

The discipline is in the other half. The injected MGF or PEG-MGF peptide has essentially no human efficacy trials behind it, native MGF is cleared in minutes (the whole reason PEG-MGF exists), the reported doses are community conventions rather than validated figures, and the product is an unapproved research chemical that is banned in sport. The honest label is investigational, with a mechanism that is more convincing than its human proof. If you take one thing from this hub, let it be the gap between "activates muscle stem cells in a dish" and "builds muscle in a person," and the value of a qualified clinician in navigating it. From here, the natural next reads are the IGF-1 LR3 guide, how to vet peptide quality, and are peptides legal.

Sources

• Wikipedia. "Mechano growth factor." Retrieved 2026-06-16. https://en.wikipedia.org/wiki/Mechano_growth_factor
• Zabłocka B, Goldspink PH, Goldspink G, Górecki DC. "Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?" Frontiers in Endocrinology, 2012. Retrieved 2026-06-16. https://pmc.ncbi.nlm.nih.gov/articles/PMC3485521/
• Schlegel W, Raimann A, Halbauer D, et al. "Insulin-Like Growth Factor I (IGF-1) Ec/Mechano Growth Factor — A Splice Variant of IGF-1 within the Growth Plate." PLoS ONE, 2013. Retrieved 2026-06-16. https://pmc.ncbi.nlm.nih.gov/articles/PMC3795771/
• Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. "Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages." Mechanisms of Ageing and Development, 2011. PMID 21354439. Retrieved 2026-06-16. https://pubmed.ncbi.nlm.nih.gov/21354439/
• UniProt Consortium. "P05019 — Insulin-like growth factor I (Human)." Retrieved 2026-06-16. https://www.uniprot.org/uniprotkb/P05019/entry
• World Anti-Doping Agency. "The Prohibited List" (Section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics). Retrieved 2026-06-16. https://www.wada-ama.org/en/prohibited-list
• Wikipedia. "List of drugs banned by the World Anti-Doping Agency." Retrieved 2026-06-16. https://en.wikipedia.org/wiki/List_of_drugs_banned_by_the_World_Anti-Doping_Agency
• Superpower. "MGF (Mechano Growth Factor): A Research Guide." Retrieved 2026-06-16. https://superpower.com/guides/mgf-mechano-growth-factor
• PeptideInsight. "MGF (Mechano Growth Factor)." Retrieved 2026-06-16. https://peptideinsight.com/en/peptides/mgf